ArticleCerebellum (London, England)2025
Spinocerebellar Ataxia 44 Caused by a Novel GRM1 Variant: Reviewing the Contrasting Pathogenic Mechanisms Underlying Two GRM1-Associated Hereditary Ataxias.
Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular and Cellular Mechanisms of Synaptogenesis and Synaptic Refinement During Cerebellar Circuit Formation.International journal of molecular sciences · 2026Review
- How Early Should I Refer My Patient? The Benefits of a Quick Ophthalmic Referral in Spinocerebellar Ataxias, a Case Series and Literature Review.Brain sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GRM1 encodes type 1 metabotropic glutamate receptor (mGluR1). Its pathogenic variants are associated with the rare autosomal recessive cerebellar ataxia 13 (SCAR13) due to loss of mGluR1 function, and the even rarer spinocerebellar ataxia 44 (SCA44) due to a gain-of-function molecular basis. We report a new case of SCA44 caused by a novel and de novo GRM1 variant c.2303 C > T (p.Thr768Ile), which was considered "likely pathogenic" by the American College of Medical Genetic criteria (PS2, PM2, PP3). This variant was predicted to lead to a stability effect on mGluR1 in the evaluation with DynaMut2, like the other known SCA44 GRM1 variants and in contrast to lower stability or destabilizing effects for SCAR13 missense variants. The affected residue Thr768 was located close to the binding pockets of allosteric modulators and within the highly conserved cholesterol recognition association/interaction consensus motif. Collectively, this novel GRM1 variant caused SCA44 by increasing the constitutive activity of mGluR1. Our findings underscore the distinct molecular mechanisms of mGluR1 aberration for the two GRM1-associated hereditary ataxias, and provide a mechanism-relevant prospect in the pharmacological therapies for restoring mGluR1 function.
Indexed as
Identifiers
40199824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.